1 / 30

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL) or their combination (L + T) in the adjuvant treatment of HER2-positive <br />early breast cancer (EBC).

mac
Download Presentation

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL) or their combination (L + T) in the adjuvant treatment of HER2-positive <br />early breast cancer (EBC) Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  2. TARGETING HER2 IN BREAST CANCER: EVOLVING CONCEPTS Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  3. Slide 3 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  4. Slide 4 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  5. Slide 5 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  6. Slide 6 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  7. Slide 7 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  8. Primary Endpoint Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  9. SECONDARY EndpointS Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  10. STAtiStical considerations Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  11. Current Analysis Plan Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  12. Slide 12 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  13. CONSORT TABLE Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  14. Slide 14 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  15. Distribution of the Stratification Factors by Treatment Arm Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  16. Distribution of patient characteristics by Treatment Arm Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  17. Slide 17 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  18. DISEASE-FREE SURVIVAL (DFS) ANALYSIS Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  19. DFS BY Hormone Receptor Status Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  20. DFS by Chemotherapy Timing Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  21. OVERALL SURVIVAL (OS) ANALYSIS Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  22. DFS NON-INFERIORITY ANALYSIS<br />Note: Null hypothesis hazard ratio is 1.11 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  23. Slide 23 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  24. PROPORTION OF PATIENTS RECEIVING ≥ 85% OF THE PLANNED DOSE OF ANTI-HER2 DRUGS Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  25. Slide 25 Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  26. MAIN DIFFERENCES IN AEs BY TREATMENT ARM Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  27. CARDIAC SAFETY Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  28. CONCLUSIONS (I) Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  29. CONCLUSIONS (II) Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

  30. Acknowledgements Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

More Related